Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07089784 | Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) | PHASE1 | COMPLETED | 46 | — | — | Sep 22, 2025 | May 4, 2026 | May 22, 2026 | 11 | United States |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Arm | Type | Description |
|---|---|---|
| MK-2828 | EXPERIMENTAL | Participants receive daily MK-2828 for 28 days. |
| Placebo | PLACEBO_COMPARATOR | Participants receive daily placebo for 28 days. |
| Name | Type | Description |
|---|---|---|
| MK-2828 | DRUG | Oral capsule of MK-2828 taken once per day for 28 days. |
| Placebo | DRUG | Placebo to match MK-2828 oral capsule, taken once per day for 28 days. |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * With the exception of type 2 diabetes mellitus (T2DM), is in generally good health * Has a history of T2DM for ≥1 year at the time of screening based on self-reporting * Has a baseline HbA1C level of ≤1...